PF-114 Uses, Dosage, Side Effects and more
PF-114 is under investigation in clinical trial NCT02885766 (Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of PF-114 for Oral Administration in Adults With Ph+ Chronic Myeloid Leukemia, Which is Resistant to the 2-nd Generation Bcr-Abl Inhibitors or Has T315I Mutation in the BCR-ABL Gene).
| Trade Name | PF-114 |
| Generic | PF-114 |
| Type | |
| Formula | C29H27F3N6O |
| Weight | Average: 532.571 Monoisotopic: 532.219844002 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
